Century Therapeutics Stock Alpha and Beta Analysis
| IPSC Stock | USD 2.42 0.11 4.76% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Century Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Century Therapeutics over a specified time horizon. Remember, high Century Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Century Therapeutics' market risk premium analysis include:
Beta 1.57 | Alpha 2.44 | Risk 9.51 | Sharpe Ratio 0.28 | Expected Return 2.71 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Century Therapeutics Backtesting, Century Therapeutics Valuation, Century Therapeutics Correlation, Century Therapeutics Hype Analysis, Century Therapeutics Volatility, Century Therapeutics History and analyze Century Therapeutics Performance. Century Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Century Therapeutics market risk premium is the additional return an investor will receive from holding Century Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Century Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Century Therapeutics' performance over market.| α | 2.44 | β | 1.57 |
Century Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Century Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Century Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Century Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Century Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Century Therapeutics shares will generate the highest return on investment. By understating and applying Century Therapeutics stock market price indicators, traders can identify Century Therapeutics position entry and exit signals to maximize returns.
Century Therapeutics Return and Market Media
The median price of Century Therapeutics for the period between Sat, Oct 25, 2025 and Fri, Jan 23, 2026 is 0.59 with a coefficient of variation of 62.87. The daily time series for the period is distributed with a sample standard deviation of 0.55, arithmetic mean of 0.87, and mean deviation of 0.41. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 5000 shares by Gregory Russotti of Century Therapeutics at 2.9978 subject to Rule 16b-3 | 11/04/2025 |
2 | Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | 11/13/2025 |
3 | Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery | 12/02/2025 |
4 | Disposition of 463 shares by Pfeiffenberger Brent of Century Therapeutics at 0.526 subject to Rule 16b-3 | 12/10/2025 |
5 | Century Therapeutics Adds Veteran Deal-Makers to Board as Pipeline Nears Clinic - MyChesCo | 12/16/2025 |
6 | Brent Pfeiffenberger Acquires 52,000 Shares of Century Therapeutics Stock | 12/18/2025 |
7 | Acquisition by Chad Cowan of 58060 shares of Century Therapeutics at 0.8483 subject to Rule 16b-3 | 12/22/2025 |
8 | Century Therapeutics, Inc. Sees Significant Decrease in Short Interest - MarketBeat | 12/26/2025 |
9 | Disposition of 1611 shares by Chad Cowan of Century Therapeutics at 0.995 subject to Rule 16b-3 | 01/02/2026 |
10 | Century Therapeutics Secures Oversubscribed 135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1... | 01/08/2026 |
11 | Century Therapeutics Highlights Progress in Immune-Evasive Cell Therapies - TipRanks | 01/12/2026 |
12 | Deep Track Capital, LPs Strategic Acquisition of Century Therap - GuruFocus | 01/22/2026 |
About Century Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Century or other stocks. Alpha measures the amount that position in Century Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Interest Debt Per Share | 0.82 | 0.68 | 0.62 | 0.52 | Revenue Per Share | 0.0377 | 0.0838 | 0.0963 | 0.0775 |
Century Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Century Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Century Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Century Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Century Therapeutics. Please utilize our Beneish M Score to check the likelihood of Century Therapeutics' management manipulating its earnings.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Century Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Century Therapeutics Backtesting, Century Therapeutics Valuation, Century Therapeutics Correlation, Century Therapeutics Hype Analysis, Century Therapeutics Volatility, Century Therapeutics History and analyze Century Therapeutics Performance. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Century Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.